GRAIL.
American biotechnology and pharmaceutical company
- Reports this week
- 6
- Active events
- 7
- Connections
- 74
What's happening
Active this week
-
A lawsuit was filed against GRAIL in the Northern District of California.Well supported13 reports
-
A lawsuit was filed in New York City involving the company GRAIL.Well supported18 reports4 developments inside
-
GRAIL disclosed insider transactions via SEC filing while its stock traded on the Nasdaq exchange on June 5, 2026.Well supported5 reports
-
A study conducted at Mayo Clinic on September 24 validated the efficacy of Grail's multi-cancer early detection test.Some support1 report
-
Grail is conducting trials with the NHS, seeking FDA approval for its Galleri test, and presenting data at ASCO.Well supported5 reports
-
The FDA is evaluating GRAIL's Galleri test as a breakthrough device, with Medicare coverage depending on the thorough FDA vetting.Well supported5 reports2 developments inside
-
A key meeting was held to review the Galleri blood test developed by GRAIL.Some support1 report
Earlier this month
-
GRAIL and Exelixis, both healthcare companies, are competing for investment.Some support1 report
-
GRAIL and Kalaris Therapeutics are competing for market share in the healthcare sector.Some support1 report
-
GRAIL utilizes a central laboratory in North Carolina and leverages Quest locations for blood sample collection for its multi-cancer early detection test.Some support1 report
One to three months ago
-
TD Cowen provided a buy rating on GRAIL shares on August 6, 2026.Some support3 reports
-
GRAIL is pursuing commercialization and expansion of its Galleri test into Asian markets, including a collaboration in South Korea.Some support1 report
-
The company GRAIL is based in New York.Some support1 report
-
Due to trial failure, GRAIL's stock price has plummeted by over 50%.Some support2 reports
Gone quiet
No new reports in 90+ days-
An investor rights law firm reminds purchasers regarding the class action lawsuit against GRAIL.Well supported4 reports
-
GRAIL conducted an NHS-Galleri trial and a class action lawsuit was filed in the Northern District.Some support4 reports
-
FSK is involved in a class action lawsuit, represented by Robbins Geller Rudman & Dowd LLP.Some support5 reports1 development inside
-
GRAIL common stock purchasers are being notified in New York.Some support1 report
-
Phillip Kim was contacted regarding the ongoing class action lawsuit against GRAIL.Some support2 reports
-
GRAIL filed reports with the SEC on June 18, 2026.Some support1 report
-
Grail was formed following a spin-off from Illumina, and Morgan Stanley reiterated its 'Equal Weight' stance on the companies.Speculative3 reports
-
Renee Gala, a former executive at GRAIL, was noted on July 11, 2025.Some support1 report
-
Galleri is the multi-cancer early detection test developed by GRAIL.Some support1 report
-
Dynatrace announced results from Boston, revealing that its platform is powered by GRAIL and led by CEO Rick McConnell.Some support4 reports
-
GRAIL reported an impairment of assets related to its acquisition of Illumina.Some support2 reports
-
GRAIL is headquartered in Menlo Park, CA.Some support4 reports
No events began in the chosen period. Widen it, or reset.
Around GRAIL this week
News at the entities that move GRAIL most-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves GRAIL
-
Illumina StructuralAnalysis suggests that both Moderna and Illumina stocks are currently overvalued.Moves GRAIL
-
New York StructuralState data drives calls for stronger regulations regarding the use of data in New York.Moves GRAIL
-
Medicare StructuralLeaders call for slowing AI development pace, concurrent with an AI model built by OpenAI being hacked via the Medicare portal.Moves GRAIL
-
Tricare OperationalCRDAMC hosted a health fair at Fort Hood featuring information about the TRICARE health program.Moves GRAIL
-
Mayo Clinic OperationalMayo Clinic researchers presented findings at the ASTRO meeting in Boston.Moves GRAIL
Connections
The 40 strongest of 74, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Illumina Structural
GRAIL maintains a structural financial relationship with Illumina as its largest shareholder and through ongoing royalty obligations.
-
Food and Drug Administration Structural
Grail seeks market approval for its Galleri product from the Food and Drug Administration (FDA).
-
Canyon Structural
The product line associated with GRAIL utilizes Canyon as the manufacturer and developer of the Grail bike series.
-
National Health Service Transactional
GRAIL is conducting a clinical trial with the NHS for the implementation of the Galleri test.
-
Dynatrace Structural
Grail provides the core data lakehouse foundation and architecture for Dynatrace's AI platform.
-
Medicare Structural
GRAIL's market access and revenue generation depend structurally on Medicare's reimbursement decisions following FDA vetting.
-
Tricare Operational
Tricare's coverage decisions enable GRAIL's diagnostic tests to gain market accessibility and expand its addressable population.
-
athenahealth Structural
GRAIL integrates its test ordering into athenahealth's platform, establishing a partnership for test distribution.
Show all 40 connections
-
FDA Structural
GRAIL's commercial viability and product development are structurally dependent on FDA regulatory review and approval.
-
New York Structural
GRAIL is subject to legal and regulatory actions and is based within the jurisdiction of New York.
-
National Health Service Structural
GRAIL's products are undergoing performance testing and validation within the operational framework of the National Health Service.
-
Quest Diagnostics Operational
GRAIL integrates its diagnostic tests into Quest's collection and testing network, leveraging Quest's infrastructure for service delivery.
-
IBM Operational
GRAIL mission data is integrated into the foundation model utilized by IBM.
-
Northern District Transactional
GRAIL is involved in a class action lawsuit pending in the Northern District Court.
-
Megan Hall Structural
Megan Hall serves as the VP of medical affairs for Grail.
-
Shimano Structural
Grail bikes rely on Shimano drivetrains as a functional component, establishing a supply chain dependency.
-
Robbins Geller Rudman & Dowd LLP Transactional
The law firm is leading a class action lawsuit against the company.
-
WHOOP Operational
WHOOP provides access to GRAIL's multi-cancer early detection test.
-
Exelixis Operational
Both companies are healthcare entities that compete for investment in the market.
-
American Society of Clinical Oncology Operational
Grail presented clinical data at the American Society of Clinical Oncology annual meeting to strengthen its scientific case.
-
SEC Structural
GRAIL operates under the mandatory regulatory oversight of the SEC regarding financial disclosures and insider trading activity.
-
Mayo Clinic Operational
Mayo Clinic conducted a study that validated the efficacy of Grail's test.
-
Mizuho Mentioned together
Mizuho raised its price target for GRAIL, indicating market assessment of A by B.
-
New York Shared context
A lawsuit announcement involving GRAIL was observed to originate in New York.
-
North Carolina Shared context
GRAIL's central laboratory is located in North Carolina.
-
TD Cowen Mentioned together
TD Cowen provides investment ratings and coverage on GRAIL shares.
-
Nvidia Mentioned together
Nvidia is referenced as a size comparison point for GRAIL.
-
Northern District Shared context
GRAIL is involved in a lawsuit that is pending in the Northern District of California.
-
England Shared context
Grail conducted a clinical trial within the geographical and regulatory context of England.
-
S&P Global Market Intelligence Mentioned together
S&P Global Market Intelligence tracks and reports on GRAIL's stock performance.
-
Josh Wilson Transactional
Josh Wilson represents investors in securities litigation concerning Grail.
-
New York City Shared context
GRAIL is involved in a class action lawsuit that is being processed in New York City.
-
Los Angeles Shared context
GRAIL's legal challenges are tied to a law firm office situated in Los Angeles.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada has begun providing financial coverage and analysis of GRAIL stock.
-
Phillip Kim Transactional
Phillip Kim is involved in a legal dispute (lawsuit/class action) concerning GRAIL.
-
Nasdaq Shared context
GRAIL's stock is listed and traded on the Nasdaq exchange.
-
MarketBeat Mentioned together
MarketBeat tracks GRAIL by including it in its aggregated consensus rating data.
-
Samsung C&T Corporation Operational
GRAIL and Samsung C&T Corporation are collaborating to commercialize Galleri in South Korea.
-
Rosen Mentioned together
The relationship between GRAIL and Rosen is not defined by the available evidence.
-
company Shared context
GRAIL is identified as a company involved in a class action lawsuit.
History
Events by the month they beganSeptember 2026
4 events- A study conducted at Mayo Clinic on September 24 validated the efficacy of Grail's multi-cancer early detection test.
- A key meeting was held to review the Galleri blood test developed by GRAIL.
- GRAIL and Exelixis, both healthcare companies, are competing for investment.
- GRAIL and Kalaris Therapeutics are competing for market share in the healthcare sector.
August 2026
4 events- GRAIL utilizes a central laboratory in North Carolina and leverages Quest locations for blood sample collection for its multi-cancer early detection test.
- TD Cowen provided a buy rating on GRAIL shares on August 6, 2026.
- GRAIL is pursuing commercialization and expansion of its Galleri test into Asian markets, including a collaboration in South Korea.
- The company GRAIL is based in New York.
June 2026
18 events- A lawsuit was filed against GRAIL in the Northern District of California.
- A lawsuit was filed in New York City involving the company GRAIL.
- GRAIL disclosed insider transactions via SEC filing while its stock traded on the Nasdaq exchange on June 5, 2026.
- Grail is conducting trials with the NHS, seeking FDA approval for its Galleri test, and presenting data at ASCO.
- The FDA is evaluating GRAIL's Galleri test as a breakthrough device, with Medicare coverage depending on the thorough FDA vetting.
- Due to trial failure, GRAIL's stock price has plummeted by over 50%.
- An investor rights law firm reminds purchasers regarding the class action lawsuit against GRAIL.
- GRAIL conducted an NHS-Galleri trial and a class action lawsuit was filed in the Northern District.
- FSK is involved in a class action lawsuit, represented by Robbins Geller Rudman & Dowd LLP.
- GRAIL common stock purchasers are being notified in New York.
- Phillip Kim was contacted regarding the ongoing class action lawsuit against GRAIL.
- GRAIL filed reports with the SEC on June 18, 2026.
- Grail was formed following a spin-off from Illumina, and Morgan Stanley reiterated its 'Equal Weight' stance on the companies.
- Renee Gala, a former executive at GRAIL, was noted on July 11, 2025.
- Galleri is the multi-cancer early detection test developed by GRAIL.
- Dynatrace announced results from Boston, revealing that its platform is powered by GRAIL and led by CEO Rick McConnell.
- GRAIL reported an impairment of assets related to its acquisition of Illumina.
- GRAIL is headquartered in Menlo Park, CA.